What is the painkiller vs. vitamin distinction?
The painkiller vs. vitamin distinction describes whether a product solves an acute, immediate, expensive problem (a painkiller) or merely improves something that already works adequately (a vitamin). Painkillers get bought urgently with low price sensitivity; vitamins get bought slowly with high price sensitivity. The metaphor has become standard early-stage venture-investing shorthand for “must-have vs. nice-to-have.”
Why painkillers convert and vitamins don’t
Three structural reasons. (1) Budget reality — painkillers compete with the cost of the problem they solve (downtime, error rates, regulatory exposure); vitamins compete with discretionary line items that get cut first when budgets tighten. (2) Decision speed — painkiller buyers want to fix the problem now; vitamin buyers can defer the decision indefinitely. (3) Champion intensity — internal advocates for a painkiller have personal stake in the fix; vitamin champions can drop the cause without consequence.
How to test if you’re selling a painkiller
Three diagnostic questions. (1) “What were you doing before us?” — painkiller customers describe a workaround they hated (spreadsheets, manual scripts, multiple disconnected tools). Vitamin customers describe a “good enough” status quo. (2) “What happens if you don’t solve this?” — painkiller customers cite a quantifiable cost (USD/month, FTE hours, churn rate, compliance fine). Vitamin customers shrug. (3) Sales velocity — painkiller deals close in days-to-weeks; vitamin deals take months and frequently stall.
The “vitamin pivot to painkiller”
Many startups discover they’re selling a vitamin and pivot to a painkiller. This usually means: (a) finding a customer segment for whom the broad use-case has acute pain, (b) repositioning the product around the painkiller wedge while keeping the broader vitamin capabilities as expansion territory, or (c) rebuilding the product to genuinely solve a pain rather than enhance an existing process. Without this pivot, vitamin businesses struggle to reach product-market fit.
Painkiller economics
Painkiller businesses display characteristic unit economics: shorter sales cycles, higher conversion rates, lower discounting, higher retention. Blended CAC payback is typically under 9 months for B2B painkillers. Vitamin businesses tend to require 18+ month payback, longer sales cycles, and significant expansion-revenue dependency to make the math work.
Türkiye context — regulatory painkillers
Turkish regulatory deadlines create natural painkiller markets: VERBIS registration (data protection authority requirement), ETBIS registration (e-commerce authority), CASP licensing (crypto). Startups solving these compliance-deadline painkillers convert faster than those selling general “data privacy” or “compliance optimisation” vitamins.
Related: Unique Insight, Killer Feature, Hair on Fire, Wedge / Beachhead.